Target intelligence / Profile preview

Shigella sonnei (S. sonnei)

Target
S. sonnei
Molecular classification
Other
01

Overview

Shigella sonnei is a Gram-negative, rod-shaped, nonmotile, non-spore-forming bacterium and a species within the Shigella genus, responsible for approximately 90% of shigellosis cases alongside Shigella flexneri. It causes shigellosis, an acute infectious diarrheal disease transmitted via the fecal-oral route through contaminated food, water, or direct person-to-person contact, with symptoms including watery or bloody diarrhea, abdominal cramps, fever, and tenesmus appearing 1-7 days post-exposure. The bacterium invades the colonic epithelium, polymerizes host cell actin for intracellular spread, triggers cytokine-mediated inflammation, and leads to colitis with bloody, mucoid stools. While often self-limiting, untreated infections can result in complications like dehydration, seizures (especially in children), hemolytic-uremic syndrome, toxic megacolon, rectal prolapse, reactive arthritis, or bloodstream infections in immunocompromised individuals. Antibiotic resistance is increasingly reported, complicating treatment, and S. sonnei is the predominant cause of shigellosis in developed countries, originating from a clonal European ancestor around 1500 AD and now widespread globally.

Other names
Shigella sonnei bacteriumGroup D Shigella
02

Biological functions

Invasion of colonic epitheliumActin polymerization in host cellsInduction of inflammatory colitis
03

Disease associations

Infection
04

Safety considerations

Antibiotic resistanceRisk of severe dehydration, seizures, hemolytic-uremic syndrome (HUS), toxic megacolon, reactive arthritis, bloodstream infections

Beyond the preview

Go deeper on Shigella sonnei (S. sonnei).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shigella sonnei (S. sonnei).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call